Joel D Leverson
Overview
Explore the profile of Joel D Leverson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
5388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Judd A, Bawa B, Buck W, Tao Z, Li Y, Mitten M, et al.
Sci Adv
. 2024 Oct;
10(40):eado7120.
PMID: 39365864
Overexpression of the antiapoptotic protein B-cell lymphoma-extra large (BCL-X) is associated with drug resistance and disease progression in numerous cancers. The compelling nature of this protein as a therapeutic target...
2.
Juarez D, Buono R, Matulis S, Gupta V, Duong M, Yudiono J, et al.
Cancer Res Commun
. 2023 Nov;
3(12):2497-2509.
PMID: 37956312
Significance: BH3 mimetics including venetoclax hold promise for treatment of multiple myeloma but rational combinations are needed to broaden efficacy. This study presents mechanistic and clinical data to support addition...
3.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, et al.
Nat Med
. 2022 Apr;
28(5):1097.
PMID: 35484266
No abstract available.
4.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, et al.
Nat Med
. 2022 Mar;
28(3):557-567.
PMID: 35241842
Myelodysplastic syndromes (MDS) are heterogeneous neoplastic disorders of hematopoietic stem cells (HSCs). The current standard of care for patients with MDS is hypomethylating agent (HMA)-based therapy; however, almost 50% of...
5.
Ahmadinejad F, Bos T, Hu B, Britt E, Koblinski J, Souers A, et al.
Mol Pharmacol
. 2021 Dec;
101(3):168-180.
PMID: 34907000
Therapeutic outcomes achieved in head and neck squamous cell carcinoma (HNSCC) patients by concurrent cisplatin-based chemoradiotherapy initially reflect both tumor regression and tumor stasis. However, local and distant metastasis and...
6.
Popovic R, Dunbar F, Lu C, Robinson K, Quarless D, Warder S, et al.
Am J Hematol
. 2021 Nov;
97(2):E47-E51.
PMID: 34779028
No abstract available.
7.
Cathelin S, Sharon D, Subedi A, Cojocari D, Phillips D, Leverson J, et al.
Leukemia
. 2021 Nov;
36(3):869-872.
PMID: 34743189
No abstract available.
8.
Ludwig L, Hawley K, Banks D, Thomas-Toth A, Blazar B, McNerney M, et al.
Cell Death Dis
. 2021 Oct;
12(11):1005.
PMID: 34707089
BH3 mimetics are increasingly used as anti-cancer therapeutics either alone or in conjunction with other chemotherapies. However, mounting evidence has also demonstrated that BH3 mimetics modulate varied amounts of apoptotic...
9.
Kater A, Slinger E, Cretenet G, Martens A, Balasubramanian S, Leverson J, et al.
Blood Adv
. 2021 Sep;
5(23):5410-5414.
PMID: 34555843
The covalent inhibitor of Bruton's tyrosine kinase ibrutinib and the specific Bcl-2 inhibitor venetoclax are both highly efficacious single-agent drugs in the treatment of chronic lymphocytic leukemia (CLL). Based on...
10.
Tong Y, Florjancic A, Clark R, Lai C, Mastracchio A, Zhu G, et al.
ACS Med Chem Lett
. 2021 Jul;
12(7):1108-1115.
PMID: 34267880
Cyclin-dependent kinase 9 (CDK9) is a serine/threonine kinase involved in the regulation of transcription elongation. An inhibition of CDK9 downregulates a number of short-lived proteins responsible for tumor maintenance and...